Analyst Expects Certara to Perform Well Despite Closing at $17.52
June 28, 2023
☀️Trending News
Analyst Dan Yergin believes that Certara ($NASDAQ:CERT) Inc., despite closing the day at $17.52, -0.11% lower than its previous closing price of $17.54, will have a good performance in the near future. Certara Inc. is a publicly traded biopharmaceutical research and development company based in Waltham, Massachusetts. They specialize in developing models and software that helps to optimize the drug development process as well as providing clinical trial services and consulting to life science companies.
The company’s stock is highly correlated with the success of the pharmaceutical industry, as their software and services are critical to the development of new drugs and therapies. Given Dan Yergin’s positive outlook on the company’s stock, investors are encouraged to hold onto their shares or consider investing in the company.
Share Price
Analysts are still expecting a bright future for Certara Inc. despite the stock closing at $17.52 on Friday. The stock opened at $17.3, representing a 0.3% decrease from its previous day closing price of $17.6. Despite the short term dip in the stock price, analysts remain optimistic in the long term prospects of Certara Inc..
Many have highlighted the company’s strong financial performance and competitive advantage in the market as reasons why they remain bullish on the stock. They have also noted that Certara Inc. is well placed to benefit from the current business environment and should continue to perform well in the coming months. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Certara. More…
| Total Revenues | Net Income | Net Margin |
| 344.39 | 13.88 | 4.0% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Certara. More…
| Operations | Investing | Financing |
| 92.7 | -21.89 | -6.69 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Certara. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.57k | 481.7 | 6.79 |
Key Ratios Snapshot
Some of the financial key ratios for Certara are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 17.2% | 18.4% | 10.9% |
| FCF Margin | ROE | ROA |
| 23.3% | 2.2% | 1.5% |
Analysis
At GoodWhale, we conducted an analysis of CERTARA’s financials and the results were promising. Our Star Chart shows that CERTARA is strong in growth, medium in profitability and weak in asset and dividend. The high health score of 8/10 with regard to its cashflows and debt indicates that CERTARA is capable to pay off debt and fund future operations. Based on our assessment, we have classified CERTARA as ‘cheetah’, a type of company that achieved high revenue or earnings growth but is considered less stable due to lower profitability. Therefore, investors who are looking for high returns may find CERTARA an interesting option as the company offers a good growth potential and relatively low volatility. However, due to its lower profitability, this type of company may also be risky for those investors who are looking for more predictable returns. Therefore, careful consideration must be taken before investing in CERTARA. Certara_to_Perform_Well_Despite_Closing_at_17.52″>More…
Peers
The competition in the genomics market is heating up as Certara Inc goes up against 10x Genomics Inc, Cambridge Cognition Holdings PLC, and Schrodinger Inc. All four companies are vying for a piece of the market share in this rapidly growing industry. So far, Certara Inc has been the most successful, but the other three are not far behind.
– 10x Genomics Inc ($NASDAQ:TXG)
As of 2022, 10x Genomics Inc has a market cap of 2.93B. The company’s Return on Equity for that year was -10.81%. 10x Genomics is a company that provides sequencing and gene editing services.
– Cambridge Cognition Holdings PLC ($LSE:COG)
Cambridge Cognition Holdings PLC is a neuropsychological testing company. The company develops and commercializes cognitive tests used by clinicians and researchers to assess brain function in patients with neurological and psychiatric disorders. Cambridge Cognition’s tests are used in clinical trials to measure the efficacy of new treatments and to screen patients for clinical studies. The company’s products are also used by pharmaceutical companies to support marketing claims for cognitive enhancing drugs.
– Schrodinger Inc ($NASDAQ:SDGR)
Schrodinger Inc is a publicly traded company with a market capitalization of 1.55 billion as of 2022. The company has a return on equity of -15.16%. Schrodinger is a provider of advanced molecular simulations and enterprise software solutions. The company’s flagship product, Maestro, is a molecular modeling and simulation software platform used by scientists to predict the behavior of complex molecules and materials.
Summary
It specializes in modeling and simulation technologies, software, and services designed to optimize drug development and regulatory review processes. Recent analysis suggests that Certara Inc. may perform well in the near future due to a variety of factors. These include a variety of successful product launches, strong partnerships with leading pharmaceutical companies, and a focus on data-driven solutions that enable faster research and review processes.
Additionally, analysts believe that the company’s focus on quality, transparency, and customer service will lead to ongoing growth and success. Investors may find value in Certara Inc. due to its potential for profitable long-term investments.
Related Posts
Recent Posts
